Compare FSP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | XGN |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 110.8M |
| IPO Year | N/A | 2019 |
| Metric | FSP | XGN |
|---|---|---|
| Price | $0.79 | $3.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 349.4K | ★ 703.9K |
| Earning Date | 02-11-2026 | 03-10-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | $63,599,000.00 |
| Revenue This Year | $4.36 | $21.40 |
| Revenue Next Year | $0.81 | $14.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $0.82 | $2.67 |
| 52 Week High | $2.09 | $12.23 |
| Indicator | FSP | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.75 | 20.71 |
| Support Level | $0.82 | $3.53 |
| Resistance Level | $0.92 | $4.01 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 4.17 | 9.37 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.